Computational repositioning of ethno medicine elucidated gB-gH-gL complex as novel anti herpes drug target

Basha et al.
Computational repositioning of ethno medicine elucidated gB-gH-gL complex as novel anti herpes drug target

Syed Hussain Basha1*, Deepthi Talluri2 and Nalini Prasad Raminni3

Abstract

Background: Herpes viruses are important human pathogens that can cause mild to severe lifelong infections with high morbidity. They remain latent in the host cells and can cause recurrent infections that might prove fatal. These viruses are known to infect the host cells by causing the fusion of viral and host cell membrane proteins. Fusion is achieved with the help of conserved fusion machinery components, glycoproteins gB, heterodimer gH-gL complex along with other non-conserved components. Whereas, another important glycoprotein gD without which viral entry to the cell is not possible, acts as a co-activator for the gB-gH-gL complex formation. Thus, this complex formation interface is the most promising drug target for the development of novel anti-herpes drug candidates. In the present study, we propose a model for binding of gH-gL to gB glycoprotein leading from pre to post conformational changes during gB-gH-gL complex formation and reported the key residues involved in this binding activity along with possible binding site locations. To validate the drug targetability of our proposed binding site, we have repositioned some of the most promising in vitro, in vivo validated anti-herpes molecules onto the proposed binding site of gH-gL complex in a computational approach.

Methods: Hex 6.3 standalone software was used for protein-protein docking studies. Arguslab 4.0.1 and Accelrys Discovery Studio 3.1 Visualizer softwares were used for semi-flexible docking studies and visualizing the interactions respectively. Protein receptors and ethno compounds were retrieved from Protein Data Bank (PDB) and Pubchem databases respectively. Lipinski’s Filter, Osiris Property Explorer and Lazar online servers were used to check the pharmaceutical fidelity of the drug candidates.

Results: Through protein-protein docking studies, it was identified that the amino acid residues VAL342, GLU347, SER349, TYR355, SER388, ASN395, HIS398 and ALA387 of gH-gL complex play an active role in its binding activity with gB. Semi flexible docking analysis of the most promising in vitro, in vivo validated anti-herpes molecules targeting the above mentioned key residues of gH-gL complex showed that all the analyzed ethno medicinal compounds have successfully docked into the proposed binding site of gH-gL glycoprotein with binding energy range between -10.4 to -6.4 K.cal./mol.

Conclusions: Successful repositioning of the analyzed compounds onto the proposed binding site confirms the drug targetability of gH-gL complex. Based on the free binding energy and pharmacological properties, we propose 3-chloro phenyl) methyl-3,4,5 trihydroxybenzoate as worth a small ethno medicinal lead molecule for further development as potent anti-herpes drug candidate targeting gB-gH-gL complex formation interface.

Keywords: Herpes simplex virus, gB-gH-gL complex, Ethnomedicine, Docking, (3-chloro phenyl) methyl-3, 4, 5 trihydroxybenzoate

* Correspondence: hassainbasha53@gmail.com
1Independent Researcher, 117-D, WWSC, Guntupalli, Ibrahimpatnam, Vijayawada 521 241, India
Full list of author information is available at the end of the article

© 2013 Basha et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Almost 85% of the world population are infected with Herpes Simplex Virus type 1 and type 2 (HSV-1 and HSV-2), which are two members of Herpesviridae family [1]. HSV infects epithelial tissues primarily and then spreads to peripheral nervous system, where it establishes latency in the neurons. Recurrent HSV-1 and HSV-2 infections typically cause oral and genital lesions respectively [2]. HSV infections are more often in people with suppressed immune system like those suffering from AIDS than others [3]. These viruses are known to infect the host cells by causing the fusion of viral and host cell membrane proteins. Fusion is achieved with the help of conserved fusion machinery components that consists of glycoproteins gB, heterodimer gH-gL complex along with other non-conserved components. Formation of gB-gH-gL complex is critical for herpes viral entry into the host cell, thus making this interface the most promising drug target. During the process of this complex formation, gB was proposed to undergo dramatic conformational rearrangements (in a umbrella fashion) as shown in Figure 1 and direct binding of gH-gL was thought to be the trigger for this conformational rearrangements. Complete structural features of gB and gH-gL glycoproteins along with their proposed mode of actions can be found elsewhere in detail [4,5]. Whereas, another important glycoprotein gD, without which viral entry to the cell is not possible, acts as a co-activator for the gB-gH-gL complex formation [6,7].

Role of ethnomedicine in finding novel antitherpes drugs

The nucleoside analog acyclovir, a widely used anti-herpes drug, is unable to cure the chronic infections and recurrence. Use of this drug often leads to the development of viral resistance coupled with side effects and viral latency [8]. Therefore discovery of novel antitherpes drugs with high specificity to inhibit the viral infection deserves great effort. On the other hand, a wide array of antimicrobial compounds with antiviral activity is described in traditional medical literature. Traditional medicine enjoys new found interest among microbiologists because of increasing antibiotic resistance and limited life span of conventional antimicrobials. It is a common practice in various fields of Biomedicine to choose plants described in traditional medicine for finding new successful therapeutic agents [9]. Most of the ethno medicinal compounds were ignored by medical practitioners despite of their proven in vitro and in vivo antiviral properties due to lack of evidence on their mode of action, effective dosage, chemical composition and toxicity [10].

Recent studies have reported promising anti Herpes viral activities of several plant extracts, some of the active constituents of this plant extracts are reported to have potential to interfere with RNA and protein synthesis, DNA replication, cellular fusion, attachment and penetration, virus entry and target cell binding, whereas some are thought to interfere in more than one step of herpes virus life cycle, resulting in complementary mechanisms of action to the existing antiviral drugs, as reviewed elsewhere in the literature [11]. In this scenario, this present work is an attempt to elucidate the possible mode of action of various promising in vitro, in vivo validated anti herpes ethno medicinal compounds to inhibit the viral fusion mechanism by attenuating the gB-gH-gL complex formation interface in a computational approach.

Methods

Preparation of protein receptor

The crystal structures of glycoprotein B (gB) (PDB ID: 2GUM) [4] and gH-gL complex (PDB ID: 3M1C) [5] of Herpes simplex virus, which were resolved using X-Ray diffraction method with a resolution factor of 2.10 Å and 3.00 Å respectively were obtained from Protein Data Bank (PDB) [12]. Methodology adapted for the preparation of protein receptor gH-gL complex for the semi flexible docking studies was described elsewhere in detail [13]. The modified structure so obtained was saved in .pdb format and used for all docking studies.

![Figure 1 Pictorial representation of proposed model by Heldwein, EE et.al, [4] for pre to post fusion conformational changes in gB.](image-url)
Selection and preparation of ligands

Structures of the ethno medicinal compounds with proven in vitro and in vivo activity against herpes as reviewed elsewhere in literature [11] were retrieved from Pubchem database [14]. All the compounds retrieved were screened with ADME constraints according to Lipinski’s rule. Finally, 29 compounds were selected for further studies, which were in accordance with Lipinski’s rule. Preparation of the selected ligands was done using Arguslab 4.0.1 software [15], addition of missing hydrogen atoms and fidelity of all bonds was checked using “add hydrogens” and “Clean Hybridization” options respectively. Geometry optimization was done using UFF Molecular Mechanics (MM) method [16-20]. Finally, all the compounds were saved in .mol format for further docking studies.

Protein-protein docking

Protein-protein docking was performed using Hex 6.3 software [21] between Domain II of glycoprotein gB (receptor) and H2 Domain of gH-gL heterodimer complex (ligand). Out of 2000 possible solutions, the best solution binding mode is selected to identify the key residues involved in their binding activity. Following parameters are used in Docking controls of Hex 6.3 to get the best results: Correlation type-Shape only; FFT mode-3D; Post Processing-MM minimization; Grid dimension-0.4; Solutions-2000; Receptor range-180; Step size-7.5; Ligand range-180; Step size-7.5; Twist range-360; Step size-5.5; Distance range-40; Scan step-0.8; Substeps-0; Steric scan-18; Final search-25, whereas the parameters used in clustering controls to get the best results are as follows: Max Clusters-500; Sort solutions by-Cluster; Display clusters-Best; Cluster window-200; RMS threshold-3.0; Bumps threshold-0.

Semi-flexible docking

Docking between receptor gH-gL protein and ligand was performed using “Dock a Ligand” option of Arguslab 4.0.1 software. A spacing of 0.4 Å between the grid points was used. “ArgusDock” was selected as docking engine. Search was performed by enabling “High precision” option in Docking precision menu, “Dock” was chosen as the calculation type, “Flexible” for the ligand and “AScore” was used as the scoring function. A maximum of 150 poses were allowed to be analyzed, binding site box was set to 25 x 25 x 25 angstroms to encompass the entire active site, and each docking run was repeated three times to get the best results.

Analysis and visualization of docking simulation results

The docking results of Arguslab 4.0.1 were saved in .pdb format. Out of 150-model results, one with the least free energy bonding data was selected. Analysis, visualization of the interactions and rendering of all the docking images was done using Accelrys® Discovery Studio 3.1 Visualizer software [22].

Pharmacological properties of the compounds

Lipinski’s Filter (http://www.scfbio-iitd.res.in/utility/LipinskiFilters.jsp), Osiris Property Explorer (http://lazar.in-silico.de/predict) online servers were used to check the pharmaceutical fidelity of the drug candidates.

Molecular descriptors, such as Log P, the number of hydrogen bond donors, the number of hydrogen bond acceptors, and the molecular mass of the compounds were analyzed by utilizing Lipinski Filter. Osiris Property Explorer and Lazar were used in analyzing various attributes of the drugs, such as toxicity and drug score.

Results and discussion

Active site identification and validation

Chowdary TK et.al proposed a gB binding site in H2 domain of gH-gL complex for the gB-gH-gL complex formation through direct binding which is the key step in the formation of fusogen, subsequently leading to the viral entry into host cells [5]. Doina Atanasiu et.al, postulated that Domain II of gB contains the residues that are directly involved in gB binding to gH-gL [23]. Based on the postulates mentioned above and keeping in view of the proposed umbrella fashioned dramatic conformational rearrangements in gB glycoprotein, which was thought to be triggered by direct binding of gH-gL, lead author of this manuscript Syed Hussain Basha has hypothesized a model for pre to post conformational changes during gB-gH-gL complex formation as shown in Figure 2, and performed a protein-protein docking study between Domain II of gB and H2 domain of gH-gL complex using Hex 6.3 software to identify the key amino acid residues involved in initial contact between these two glycoproteins leading to their complex formation, and visualized that VAL 342, GLU 347, SER 349, LEU 399, GLU 401 and GLY 437 of gB glycoprotein gen bonds with LYS 435, ARG 418, GLN 438, PRO 439, TYR 355, SER 388, ASN 395, HIS 398 and ALA 387 amino acid residues of gH-gL complex forming hydrogen bonds with LYS 435, ARG 418, GLN 438, PRO 439, LEU 399, GLU 401 and GLY 437 of gB glycoprotein (Figure 3). The proposed binding sites of gB and gH-gL glycoproteins has been shown in Figure 4. For the present study, proposed binding site of gH-gL (Figure 4B) with amino acid residues VAL 342, GLU 347, SER 349, TYR 355, SER 388, ASN 395, HIS 398 and ALA 387 was defined as the binding site for the docking studies. To validate the drug targetability of our proposed active binding site in gH-gL, we have repositioned some of the most promising in vitro, in vivo validated anti-herpes molecules onto the proposed binding site of gH-gL complex in a computational docking simulation approach. However, further validation of proposed binding
site in gH-gL as much promising drug target over proposed binding site in gB has been deduced elsewhere in detail [24].

Interaction of the ethno compounds with active site
The docking results in pdb were visualized using Accelrys® Discovery Studio 3.1 Visualizer software. A total of 150 poses were visualized for each of the 29 ethno medicinal compounds to identify the model with best docking values, based on the binding energy interactions. The docking result showed that all the 29 compounds analyzed form hydrogen bonds with various amino acid residues in the target molecule, in the range of 0–8 hydrogen bonds (Table 1). Apart from hydrogen bonds, several other interactions like pi-cationic, pi-pi interactions and other non-covalent bonds have thought to play key role in stabilizing the docked compounds in the proposed binding site of gH-gL complex. In all the compounds analyzed, O atom on C = O and -OH functional groups were observed to play a key role in hydrogen bonds formation. Figures 5 and 6 depicts the interactions of the 6 best compounds analyzed towards the target binding site of gH-gL complex that displayed good pharmacological properties with no toxicity.

Binding free energy (ΔG binding)
As per the docking results (Table 1), all the 29 compounds tested docked into the active site of the target protein molecule successfully, with a binding energy ranging between -10.4 to -6.4 K.cal./mol. Out of all the compounds analyzed, (3-chloro phenyl) methyl-3,4,5 trihydroxybenzoate showed the least possible binding energy of -10.4 K.cal./mol by forming 4 hydrogen bonds with amino acid residues ASP 187, ARG 318, TYR 319 and ASN 395 (Figure 7). Whereas, Isoborneol and linalool showed the highest possible free binding energy of -6.4 K.cal./mol and -7.3 K.cal./mol respectively, with no hydrogen bond formation with any of the active site amino acid residues. Caffeoylquinic acid formed the highest possible hydrogen bonds (8 bonds) with THR 251, ARG 318, TYR 319, ASN 395 and HIS 398 amino acid residues of the target protein receptor with a
binding energy of -8.9 Kcal/mol. Whereas Lignan was unable to dock into the proposed binding site.

The argusdock values of $\Delta G$ binding given in Table 1 shows that every ligand has negative $\Delta G$, which shows that all the ethno medicinal compounds analyzed for binding with gH-gL complex are highly stable. These negative binding free energies also evidenced that the reaction is spontaneous.

**Prediction of pharmacological properties**

Lipinski Filter and Osiris Property Explorer were utilized to screen the drug candidate based on Lipinski’s Rule of Five and Oral Bioavailability. The pharmacological attributes prediction results are displayed in (Additional file 1: Table S1) and the structures of all the ethno medicinal compounds used for the study are shown in Additional file 1: Figure S1.

Based on the experimental values, it was inferred that all the ethno medicinal compounds successfully satisfied all the parameters of Lipinski’s Rule of Five with the exception of the hydrogen donor for Caffeoylquinic acid. The parameters of the Lipinski’s rule are as follows: the molecular weight must be < 500 Da, Log P < 5, the number of hydrogen donors must be < 5, the number of acceptor hydrogens must be < 10, and the refractivity molar range must be between 40–130.

As per the Veber’s rule, oral bioavailability of drugs could be measured by the molecular weight, number of

![Figure 3](image3.png)

**Figure 3** Visualization of key residues involved in gB-gH-gL complex formation. A) Amino acid residues involved in the gB-gH-gL complex formation, Blue colored amino acid residues VAL 342, GLU 347, SER 349, TYR 355, SER 388, ASN 395, HIS 398 and ALA 387 belong to gH-gL complex, whereas yellow colored amino acid residues LYS 435, ARG 418, GLN 438, PRO 439, LEU 399, GLU 401 and GLY 437 belong to gB glycoprotein. B) Hypothesized model for initial binding of gH-gL complex to gB at their H2 domain and Domain II respectively.

![Figure 4](image4.png)

**Figure 4** Visualization of the glycoproteins gB and gH-gL complex: A) Proposed binding site (green) for H2 domain of gH-gL complex in gB (for better clarity binding site is shown in post conformation state of gB) B) Proposed binding site (yellow) for Domain II of gB in gH-gL complex.
rotatable bonds (n rotb), number of hydrogen bonds, and the expanse of the drug’s polar surface (TPSA). The oral bioavailability was marked by small molecular weight (less than 500 Da); also, the number of rotatable bond must be less than 10, the number of hydrogen bond donors and acceptors must be less than 12, and TPSA values less than 140. Additional file 1: Table S1 shows that all the compounds have a good oral bioavailability, with the exception of Caffeoylquinic acid and Rosmarinic acid.

Table 1 The binding free energy docking simulation result of ethno compounds toward gH-gL complex of HSV and the number of hydrogen bonds formed along with the amino acid residues involved in the interactions

| S. No | Name of the compound                        | Binding energy in Kcal/mol | No. of H-Bonds formed with receptor | Amino acid residues involved in H-bonding |
|-------|---------------------------------------------|-----------------------------|-------------------------------------|------------------------------------------|
| 1     | Aloe-emodin                                | −9.6                        | 5                                   | ARG 318, TYR 319, SER 349 and ALA 392   |
| 2     | Allicin                                     | −7.8                        | 2                                   | TYR 319 and ASN 395                     |
| 3     | Anthra quinone                             | −9.0                        | 1                                   | HIS 398                                 |
| 4     | Apigenin                                   | −7.6                        | 2                                   | PRO 346 and ASN 395                     |
| 5     | Baicalein                                  | −7.9                        | 3                                   | ASN 395, PRO 346 and PRO 186            |
| 6     | Bisbenzylisoquinoline                      | −10.1                       | 2                                   | ASN 395 and TYR 319                    |
| 7     | Caffeic acid                               | −7.5                        | 3                                   | ARG 318, HIS 398 and THR 251            |
| 8     | Caffeoylquinic acid                        | −8.9                        | 8                                   | THR 251, ARG 318, TYR 319, ASN 395 and HIS 398 |
| 9     | Catechin                                   | −8.0                        | 4                                   | ARG 318, GLY 270 and THR 350            |
| 10    | Cochinolide                                | −9.0                        | 5                                   | ARG 318, TYR 319 and ASN 395            |
| 11    | Epiafzelechin                              | −8.3                        | 2                                   | GLY 268 and VAL 394                    |
| 12    | Galangin                                   | −8.3                        | 1                                   | PRO 186                                 |
| 13    | Isoborneol                                 | −6.4                        | 0                                   | NIL                                     |
| 14    | Kaempferol                                 | −7.9                        | 5                                   | ARG 318, ASN 395 and ALA 302            |
| 15    | Lignan                                     | NALP                        | 0                                   | NIL                                     |
| 16    | Linalool                                   | −7.3                        | 0                                   | NIL                                     |
| 17    | (3-chloro phenyl) methyl-3,4,5              | −10.4                       | 4                                   | ARG 318, TYR 319, ASP 187 and ASN 395   |
|       | trihydroxybenzoate                         |                             |                                     |                                         |
| 18    | Methylgallate                              | −8.4                        | 4                                   | THR 251, GLY 270 and HIS 398            |
| 19    | Morin                                      | −8.1                        | 2                                   | ASN 395 and SER 349                    |
| 20    | Oxyresveratrol                             | −7.2                        | 1                                   | THR 251                                 |
| 21    | Phloroglucinol                             | −7.5                        | 2                                   | GLY 268 and HIS 398                    |
| 22    | Physcion                                   | −8.9                        | 7                                   | ARG 318, ASN 395, PRO 346, SER 349 and ASP 187 |
| 23    | Quercetin                                  | −8.0                        | 5                                   | ARG 318, GLY 270 and ALA 392            |
| 24    | Resveratrol                                | −9.5                        | 2                                   | GLY 268 and HIS 398                    |
| 25    | Rhein                                      | −8.9                        | 3                                   | ARG 318 and ASP 187                    |
| 26    | Rosmarinic acid                            | −10.1                       | 4                                   | GLY 270, ARG 318 and PRO 346            |
| 27    | Wogonin                                    | −9.3                        | 5                                   | ARG 318, TYR 319 and ASN 395            |
| 28    | Yatein                                     | −7.6                        | 1                                   | ARG 318                                 |
| 29    | Zeatin                                     | −7.8                        | 4                                   | ARG 318, TYR 319 and HIS 398            |

NALP = No acceptable ligand poses.

The hydrophobicity of drugs could be inferred from Log P value. Log P Values are directly proportional to the oral hydrophobicity of the drug. More hydrophobic the drug is, higher is the ability of the drug to circulate longer in our body. It wouldn’t be easy to excrete such a drug. In the present investigation, the Log P values of the drug molecules were observed to be in the range of -0.4 to 6. The highest Log P value of 6 was observed for Bisbenzylisoquinoline, followed by 3.8 for Lignan and Yatein, which shows that Bis-benzylisoquinoline was...
the most hydrophobic molecule amongst all the analyzed. However, Anthraquinone, Galangin, Isoiborneol, Lignan, Linalool, (3-chloro phenyl) methyl-3,4,5 trihydroxybenzoate, Oxyresveratrol, Physcion, Resveratrol, Rhein, Rosmarinic acid, Wogonin and Yatein also showed good hydrophobicity with a range of log P between 2–5.

The drug score value is one such useful practical value which is a combination of variables such as drug likeness, Log P, solubility, molecular weight and toxicity risk, which could be used for the evaluation of a potential drug candidate. A drug molecule with a better drug score has a greater chance to be a drug candidate. As per the values shown in Additional file 1: Table S1, Catechin with a drug score 0.87 showed the highest possibility of being a potential drug and Zeatin with a drug score of 0.1 shown to be the least possible potential drug.
Figure 7 Docking simulation result of Best binder. A) Binding of (3-chloro phenyl) methyl-3, 4, 5 trihydroxybenzoate into the proposed binding site of gH-gL complex. B) Amino acid residues ARG 318, TYR 319, ASP 187 and ASN 395, which are involved in the binding of the compound in the proposed binding site of gH-gL complex by forming hydrogen bonds (red dotted lines) using -10.4 K.cal/mol of binding energy.
Prediction of toxicity
Osiris Property Explorer and Lazar were used to predict toxicity of the compounds in the present study. The predictions were based on the functional group similarity for the query molecule with the in vitro and in vivo validated compounds present in the database of these two online programs.

Osiris Property Explorer results were visualized using color codes. The result of toxicity analysis of all the analyzed ethno compounds is shown in Additional file 1: Table S2. Green color shows low toxic tendency, yellow shows the midcore and red color shows high tendency of toxicity.

Additional file 1: Table S2 shows that Anthraquinone, Apigenin, Caffeic acid, Galangin, Kaempferol, Linalool, Morin, Phloroglucinol, Quercetin, Resveratrol, Zeatin have high toxicity. Whereas Allicin, Bis-benzisooquinoline, Caffeoylquinic acid, Catechin, Cochinolide, Epiafzelechin, Isoborneol, Lignan, (3-chloro phenyl) methyl-3,4,5 trihydroxybenzoate, Methylgallate, Oxyresveratrol, Rhein, Ros marinic acid, Wogonin and Yatein had no toxic effect, whereas other compounds had midcore toxicity.

Lazar is a software package which is used to detect mutagenic and/or carcinogenic properties based on the similarities in functional group with mutagenic and/or carcinogenic ones present in its database. Additional file 1: Table S3 shows the results of compounds toxicity analysis by lazar. The training dataset of molecules present in Lazar program were verified by conducting an assay with Salmonella typhimurium.

Additional file 1: Table S3 shows that Aloe-emdoin, Anthraquinone, Baicalein, Bisbenzisooquinoline, Galangin, Morin, Physcion, Quercetin, Rhein, Wogonin and Zeatin have mutagenic properties. Whereas Caffeic acid, Caffeoylquinic acid, Catechin, Cochinolide, Epiafzelechin, Lignan, Linalool, (3-chloro phenyl) methyl-3,4,5 trihydroxybenzoate, Methylgallate, Oxyresveratrol, Rosmarinic acid, Wogonin and Yatein have no toxic effect, whereas other compounds had midcore toxicity. Moreover, the carcinogenicity of compounds was verified by in silico animal testing studies with Mouse. Additional file 1: Table S3 shows that all the compounds analyzed have no carcinogenicity, with the exception of Zeatin.

Screening for the best compound based on docking and drug likeliness results
It was found that (3-chloro phenyl) methyl-3,4,5 trihydroxybenzoate was the best anti herpes viral ethno medicinal compound based on its AG binding compared to other compounds followed by Bis-benzisooquinoline and Rosmarinic acid with a binding energy of around -10 K.cal/mol. However, Bis-benzisooquinoline and Rosmarinic acid have bad pharmacological and toxicity attributes, based on pharmacological properties. Rosmarinic acid has a TPSA value more in excess of threshold Veber’s rule parameter, whereas Bisbenzisooquinoline showed considerable mutagenicity. (3-chloro phenyl) methyl-3,4,5 trihydroxybenzoate showed good pharmacological attributes, since it satisfied the Lipinski’s Rule, Veber’s Rule, Log P values, toxicity and drug score threshold.

However, based on Pharmacological properties, Caffeoylquinic acid, Catechin, Cochinolide, Epiafzelechin, Lignan, (3-chloro phenyl) methyl-3,4,5 trihydroxybenzoate, Methylgallate, Oxyresveratrol, Rosmarinic acid and Yatein showed good pharmacological attributes. These compounds were found to comply with Lipinski’s rule, Veber’s rule and oral bioavailability parameters with the exception of Caffeoylquinic acid and Rosmarinic acid, because of their TPSA value exceeded the threshold of 140.

Conclusion
The binding energy analysis showed that (3-chloro phenyl) methyl-3,4,5 trihydroxybenzoate had a least binding energy value of -10.4 K.cal/mol compared to other compounds followed by Bisbenzisooquinoline and Rosmarinic acid with binding energy values of -10.1 K.cal/mol each, among all the compounds analyzed. Visualization of the interactions showed that O atom on C = O and -OH groups of all tested compounds played a major role in hydrogen bonds formation with amino acid residues of receptor molecule. Conclusively, our results strongly suggest that (3-chloro phenyl) methyl-3, 4, 5 trihydroxybenzoate is worth a lead ethno compound for developing further as a potent inhibitor against Herpes simplex virus targeting its fusion protein complex. On the other hand, successful repositioning of the analyzed compounds onto the proposed binding site of gH-gL complex shed light on its drug targetability for further investigations. However, as this present work is only a step forward towards understanding the mechanistic insights of a potent inhibitor for herpes viral entry into the host cell targeting gB-gH-gL complex interface, further in vitro and in vivo validations are required.

Additional file

Additional file 1: Table S1. The molecular descriptor values of the ethno compounds used in this study along with their pubchem compound IDs. Table S2. Toxicity of ethno compounds based on Osiris Property Explorer predictions. Table S3. Toxicity of ethno compounds based on Lazar program predictions Figure S1. Structures of the ethno compounds used in the present study.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SHB conceptualized the idea, carried out the work including acquisition of the data, analysis and interpretation of the final results and drafting the manuscript. TD assisted SHB in acquisition of the data and RNP helped with editing the manuscript. All the authors have read and approved the final manuscript.
Acknowledgement

SBH specially thank and dedicate this work to his parents Syed Abdul Khader Basha and Syed Khushheed Begum for providing the required facilities to carry out this whole work at home and for their constant encouragement and support, without which this research work wouldn’t have been possible. The authors wish to thank Dr. N. Ramesh, Principal, REVA ISM for his much-needed help. Dr. Atuturi Venu, Principal, Montessori Siva sivani Institute of Science and Technology-College of Pharmacy for extending his help and motivation. Dr. Vidyavathi N, Prof. Dept. of Biotechnology, REVA ISM for reading the earlier version of this manuscript. We gratefully acknowledge Doina Atanasiu and Ashoke Sharon for generously donating their valuable time in providing peer review for this manuscript.

Author details

1Independent Researcher, 117-D, WWSC, Guntupalli, Ibrahimpatnam, Vijayawada 521 241, India. *Montessori Siva sivani Institute of Science and Technology-College of Pharmacy, Mylavaram, Vijayawada 521 290, India.
2Department of Biotechnology, REVA Institute of Science and Management, Yelahanka, Bangalore 560 064, India.

Received: 15 February 2012 Accepted: 11 March 2013
Published: 15 April 2013

References

1. Prevention and control of Herpes virus diseases. In Clinical and laboratory diagnosis and chemotherapy. Volume 63. Bulletin of the WHO, 1985:182–185.
2. Whitley RJ. Herpes simplex viruses. In Fields Virology. Edited by Knipe DM, Howley PM. Philadelphia: Lippincott, Williams and Willis, 2001:2461–2509.
3. Wild K, Bohner T, Folkers G, Schulz GE. The structures of thymidine kinase from Herpes simplex virus type I in complex with substrates and a substrate analogue. Protein Sci 1997, 6:2097–2106.
4. Heldwein EE, Lou H, Bender FC, Cohen GH, Eisenberg RJ, Harrison SC. Crystal structure of glycoprotein B from Herpes simplex virus-1. Science 2006, 312:217–220.
5. Chowdary TK, Cairns TM, Atanasiu D, Cohen GH, Eisenberg RJ, Heldwein EE: Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol 2010, 17(7):882–888.
6. Krummenacher C, Supekar VM, Whitbeck JC, Lazear E, Connolly SA, Eisenberg RJ, Cohen GH: Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. EMBO J 2005, 24:4144–4153.
7. Eisenberg RJ, Atanasiu D, Cairns TM, Gallagher Jr, Krummenacher C, Cohen GH: Herpes Virus Fusion and Entry: A Story with Many Characters. Review, Viruses 2012, 4(5):890–892.
8. Charis PA, Cumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992, 36(8):1589–1595.
9. Cox PA, Balick M. The ethnomedical approach to drug discovery. Sci Am 1994, 270:82–87.
10. Grifo F, Rosenthal J. Biodiversity and human health. Washington DC, USA: Island Press; 1997.
11. Debraprasad C, Sonali D, Sekhar C, Bhattacharya SK. Ethnomedicines for the development of anti-herpes virus agents. Ethnomedicine: A Source of Complementary Therapeutics 2010:117–147.
12. Bernstein FC, Koetzle TF, Williams GJ, Meyer EE Jr, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi M: The Protein Data Bank: A Computer-based Archival File For Macromolecular Structures. J Mol Biol 1994, 225:503–512.
13. Hussain Basha S, Prasad RN: In-Silico screening of Plecanol and its novel substituted derivatives with Neuraminidase of H1N1 Influenza strain. BMC Research Notes 2012, 5:105.
14. Boltot E, Wang Y, Thiessen PA, Bryant SH: PubChem: Integrated Platform of Small Molecules and Biological Activities. Chapter 12. In Annual Reports in Computational Chemistry, Volume 4. Washington, DC, American Chemical Society; 2008.
15. Thompson MA: ArgusLab 4.0.1. Seattle, WA: Planaria Software LLC. [http://www.arguslab.com].
16. Rappe AK, Casevitz CJ, Colwell KS, Goddard WA III, Skiff WM, UFF: A full periodic table force field for molecular mechanics and molecular dynamics simulations. J Am Chem Soc 1992, 114:10024–10035.
17. Rappe AK, Casevitz CJ, Colwell KS, Application of a Universal force field to metal complexes. Inorg Chem 1993, 32:3438–3450.
18. Rappe AK, Goddard WA III: Charge Equilibration for molecular dynamics simulations. J Phys Chem 1991, 95:3358–3363.
19. Casevitz CJ, Colwell KS, Rappe AK: Application of a universal force field to organic molecules. J Am Chem Soc 1992, 114:10035–10046.
20. Casevitz CJ, Colwell KS, Rappe AK: Application of a universal force field to main group compounds. J Am Chem Soc 1992, 114:10046–10053.
21. Ritchie DW: Recent progress and future directions in protein-protein docking. Curr Prot Pep Sci 2008, 9(1):1–15.
22. Accelrys Software Inc: Discovery studio Visualizer 3.1. 2011. http://accelrys.com/products/discovery-studio/visualization-download.php.
23. Doina A, Whitbeck JC, de Leon MP, Lou H, Hannah BP, Cohen GH, Eisenberg RJ: Bimolecular Complementation Defines Functional Regions of Herpes Simplex Virus gB that Are Involved with gH/gL as a Necessary Step Leading to Cell Fusion. J Virol 2010, 84(8):3825–3834.
24. Hussain Basha S, Naresh Kumar K: Ligand and Structure based virtual screening studies to identify potent inhibitors against herpes virus targeting gB-gH-gL complex interface as a novel drug target. Open access sc rep 2012, 2(1):2566.